Key Press Releases

International Expert in Blood Collection Tubes joins Q-Sera

October 2, 2018

2nd October, Melbourne, Australia – Q-Sera Pty Ltd (Q-Sera) is pleased to announce the addition of international consultant and expert in the field of blood collection tubes, Franz E. Kirchmeir to our growing company to further R&D efforts and assist in the commercialization of the RAPClot™ technology.

Franz was previously the Director of Business Development at Greiner Bio-One Preanalytics at their global headquarters in Austria. He brings 20 years’ experience in the pre-analytical business sector including blood collection tubes, as well as extensive knowledge in R&D management, business development and strategic management. Q-Sera is pleased to welcome Franz to the team to help bring our technology into international markets.

Q-Sera has patented a novel class of coagulation agents for use in blood collection tubes. Q-Sera’s coagulation agent RAPClot™, a prothrombin activator, is produced recombinantly from modified cell lines using standard pharmaceutical manufacturing processes; meaning that it can be available at the required scale and low cost for use in a universal blood collection tube.

Blood collection tubes coated with RAPClot™ have been shown to produce high quality serum for accurate analyses faster than standard tubes, including cases where the blood samples contain anti-coagulants. Q-Sera is developing the RAPClot™ technology to improve the efficiency and reduce costs in the healthcare system, driving better outcomes for patients through faster testing turnaround times enabling quicker lifesaving decisions.

Franz will bring to Q-Sera expertise in international business development, technical engineering and R&D management in the field of blood collection tubes in addition to key relationships with potential international partners.  He will assist Q-Sera to further develop and commercialize Q-Sera’s revolutionary technology and introduce its benefits to global markets.

Michael Grant, CEO of Q-Sera, said, “We are absolutely pleased and excited to work with Franz, whose experience and expertise will be invaluable to Q-Sera’s efforts to bring RAPClot™ blood collection tubes into the global market.”.

Q-Sera’s innovative blood clotting technology patent granted in China

November 27, 2017

Q-Sera Pty Ltd (Q-Sera) is pleased to announce that the foundation patent for its innovative blood clotting technology, RAPClot™, has been granted in China which joins a growing list of countries where the patent has now been granted which include the EU, Japan and Australia.

Read more

Q-Sera’s innovative blood clotting technology presented at leading international scientific conference

October 23, 2017

A poster presentation on Q-Sera’s recombinant prothrombin activator RAPClot™ technology for blood collection tubes was made at the 23rd International Congress of Clinical Chemistry and Laboratory Medicine (IFCC Worldlab) in Durban, South Africa.

Read more

Australia’s deadliest snakes set to save lives in medical breakthrough / patent update

June 7, 2017

Australian developed medical technology which uses the blood clotting properties of snakes including the Australian Coastal Taipan, one of the world’s deadliest, is set to revolutionise the world of blood testing and assist the rapid diagnosis and treatment of patients in need of urgent medical attention.

Read more